1. Safety and Efficacy of Injection Tenecteplase in 4.5 to 24 Hours Imaging Eligible Window Patients with Acute Ischemic Stroke (EAST-AIS) - Study Protocol
- Author
-
Awadh Kishor Pandit, Arti Jatwani, Poorvi Tangri, Madakasira Vasantha Padma Srivastava, Rohit Bhatia, Shashank Sharad Kale, Shailesh Gaikwad, Achal Kumar Srivastava, Ajay Garg, Leve Sebastian Joseph, Deepti Vibha, Venugopalan Y. Vishnu, Rajesh Kumar Singh, Divya M. Radhakrishnan, Animesh Das, and Ayush Agarwal
- Subjects
acute ischemic stroke ,eligible window period: 4.5–24 h ,mrs ,randomized controlled trial ,study protocol ,tenecteplase ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Background and Aims: Tenecteplase is used as the standard of care treatment for thrombolysis in acute ischemic stroke (AIS) patients within 4.5 h of symptom onset. Documented reports were less certain to claim the benefits of it in an extended window period. EAST-AIS (CTRI/2022/03/040718) trial is designed to determine the success rate of thrombolysis in an extended window period for good clinical outcomes. Study Design: It is a randomized, placebo-controlled trial of tenecteplase administered within 4.5–24 h of stroke onset (with or without large vessel occlusion) based on evidence of salvageable tissue through baseline computed tomography perfusion (CTP) or magnetic resonance imaging (MRI) scan. Criteria of patient inclusion are as follows: patients of both genders (male and female), age >18 years, pre-stroke modified Ranking Scale (mRS) 5, CTP showing penumbra–ischemic core ratio >1.8, absolute difference in volume >10 ml, and ischemic core volume
- Published
- 2024
- Full Text
- View/download PDF